Serotonin syndrome in two COVID-19 patients treated with lopinavir/ritonavir
| Autor: | Miguel Mas Serrano, Isabel Pérez Tamayo, Beatriz De la Casa-Fages, Francisco Grandas, Víctor Mato Jimeno, Javier Ricardo Pérez-Sánchez, Sofia Portela Sanchez |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Coronavirus disease 2019 (COVID-19)
Serotonin syndrome Clinical Neurology Lopinavir/ritonavir medicine.disease_cause Article Pandemic Medicine Drug-induced disorder Coronavirus biology business.industry Neurological complication COVID-19 Lopinavir biology.organism_classification Virology Neurology Ritonavir Neurology (clinical) medicine.symptom business Betacoronavirus medicine.drug |
| Zdroj: | Journal of the Neurological Sciences |
| ISSN: | 0022-510X |
| DOI: | 10.1016/j.jns.2020.116944 |
| Popis: | Highlights • Two cases of Serotonin syndrome (SS) in COVID-19 patients are presented. • Lopinavir/ritonavir (LPV/r) have been widely used during the COVID-19 pandemic. • LPV/r with duloxetine and lithium triggered SS in patient 1. • LPV/r with risperidone, and probably also morphine, triggered SS in patient 2. • A Video of patient 2 shows myoclonus and ocular clonus in the context of SS. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect